Form 4: Neogenomics Director Lynn Tetrault Reports Routine Equity Compensation Transactions

Neogenomics Inc. Director Lynn A. Tetrault reported the vesting of restricted stock units into common stock and the grant of new stock options and restricted stock units, aligning her interests with shareholders.

Summary

• Lynn A. Tetrault, a Director at Neogenomics Inc. (NEO), reported transactions on June 1, 2025, related to her equity compensation.
• She acquired 12,254 shares of common stock through the exercise/release of previously reported restricted stock units (RSUs) at a price of $0.
• Following this transaction, Ms. Tetrault directly beneficially owns 73,652 shares of common stock and indirectly owns 7,000 shares through her Rollover IRA.
• Additionally, Ms. Tetrault was granted 16,107 stock options with an exercise price of $7.28, exercisable from June 1, 2026, and expiring on June 1, 2035.
• She also received a grant of 23,077 restricted stock units, exercisable from June 1, 2026, which, once vested, are not subject to expiration.
• The filing also lists existing stock options with various exercise prices and expiration dates, indicating her total derivative holdings.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it reflects routine equity compensation, including new grants, which aligns the director's interests with the company's long-term performance and retention. It is not a sale, which would typically be viewed negatively.

Positives

• The grant of new stock options and restricted stock units to a director indicates continued alignment of management and board interests with shareholder value creation.
• The vesting of restricted stock units increases the director's direct ownership in the company, demonstrating commitment.

Future Outlook

The newly granted stock options and restricted stock units for Lynn A. Tetrault are scheduled to become exercisable/vest on June 1, 2026, indicating future equity compensation events.

Industry Context

This Form 4 filing reflects routine equity compensation practices for directors in publicly traded companies, particularly common in the biotechnology and diagnostics sector like Neogenomics, to incentivize long-term performance and align interests with shareholders.

Stakeholder Impact

• Shareholders: Increased direct ownership by a director generally aligns their interests with those of shareholders, potentially fostering better long-term decision-making.
• Employees: While not directly impacting employees, such compensation structures are common across leadership, setting a precedent for executive and board incentives.

Next Steps

• The newly granted stock options and restricted stock units will become exercisable/vest on June 1, 2026, at which point Ms. Tetrault may choose to exercise options or hold vested shares.

Key Dates

Recommendation

Keywords

Neogenomics, NEO, Form 4, Insider Transaction, Director, Equity Compensation, Stock Options, Restricted Stock Units, Beneficial Ownership